Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Harm Reduct J ; 18(1): 109, 2021 10 23.
Artigo em Inglês | MEDLINE | ID: mdl-34688284

RESUMO

BACKGROUND: The combustion of tobacco is the main cause of tobacco-related morbidity and mortality. E-cigarettes are potentially disruptive innovations with considerable potential for population health. A key question is whether e-cigarettes are replacing tobacco cigarettes, which requires mapping their prevalence. Collecting information on nicotine use is difficult for many countries due to cost. The objective of this study was to derive a global estimate of e-cigarette use (vaping). METHODS: Since 2018 we have collected information on the prevalence of e-cigarette use. To estimate the prevalence of vaping in countries lacking information, we used the method of assumed similarity between countries in the same region and economic condition. Based on surveys, we calculated the average prevalence of vaping for each WHO region, World Bank income classification group, and the legal status of e-cigarettes in each country. For each of these groups the average prevalence of vaping was calculated. These values were used as substitutes for the prevalence figures in the countries with absent data. The number of vapers was calculated by taking as the denominator the adult population. RESULTS: Survey data on e-cigarette users were available for 49 countries covering 2.8 b of the adult population in 2018 and unavailable for 2.9 b. Information on vaping was lacking for half of the world's population. We estimated a total of 58.1 m vapers worldwide in 2018. By reference to market growth the data were adjusted to arrive at estimates for 2020. Results were fitted to revenue data at the 2018. For the year 2020, the projection is for 68 m vapers globally. CONCLUSIONS: Many global epidemiological studies use the method of assumed similarity between countries with shared characteristics in order to estimate missing data. The methodological limitations are likely to overestimate the global number of vapers. Our estimate of 68 m vapers indicates considerable uptake given that: e-cigarettes have been available on most markets for only a decade; there is either no support, or there is opposition to vaping in many countries; and countries which regulate e-cigarettes have controls over advertising and promotion. However, given the global scale of tobacco smoking (at 1.1 billion people), progress in adoption of alternative products is slow. Those using e-cigarettes are still a small fraction of those who smoke.


Assuntos
Sistemas Eletrônicos de Liberação de Nicotina , Produtos do Tabaco , Vaping , Adulto , Humanos , Fumantes , Fumar Tabaco
2.
Hum Psychopharmacol ; 28(4): 317-23, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23881879

RESUMO

OBJECTIVES: The recent emergence of new psychoactive compounds (novel psychoactive substances (NPS)) has raised prominent challenges in the fields of drug policy, substance use research, public health and service provision. The Recreational Drugs European Network project, funded by the European Commission, was implemented to improve the information stream to young people and professionals about effects/risks of NPS by identifying online products and disseminating relevant information through technological tools. METHODS: Regular multilingual qualitative assessments of websites, drugs fora and other online resources were carried out using the Google search engine in eight languages from collaborating countries. These included the following: the UK, Norway, Belgium, Germany, Hungary, Poland, Italy and Spain. Products were tested and prevention messages were developed and disseminated via technological tools such as interactive websites, SMS alert, social networking (Facebook, Twitter), Multimedia (You Tube), Smartphone applications (iPhone) and virtual learning environments (Second Life). RESULTS: The Recreational Drugs European Network project established itself as the first Europe-wide prevention programme designed for NPS based on the efficacy of novel information and communication technology-based forms of intervention. More than 650 NPS products and combinations were identified; relevant information was disseminated to target population and advice was given to both European Union/international agencies and national policy makers. CONCLUSIONS: Web-monitoring activities are essential for mapping the diffusion of NPS and the use of technological tools can be successfully incorporated in specific prevention programmes. Furthermore, the involvement of multi-disciplinary international partnerships was and continues to be fundamental for responding to such a prominent challenge.


Assuntos
União Europeia/organização & administração , Serviços de Informação/organização & administração , Cooperação Internacional , Internet/organização & administração , Psicotrópicos/efeitos adversos , Bases de Dados Factuais/normas , Humanos , Drogas Ilícitas/efeitos adversos , Drogas Ilícitas/química , Serviços de Informação/normas , Internacionalidade , Internet/normas , Multilinguismo , Psicotrópicos/química , Fatores de Tempo
4.
Hum Psychopharmacol ; 27(2): 145-9, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22389078

RESUMO

On the basis of the material available both in the scientific literature and on the web, this paper aims to provide a pharmacological, chemical and behavioural overview of the novel compound methoxetamine. This is a dissociative drug related to ketamine, with a much longer duration of action and intensity of effects. A critical discussion of the availability of information on the web of methoxetamine as a new recreational trend is here provided. Those methodological limitations, which are intrinsically associated with the analysis of online, non-peer reviewed, material, are here discussed as well. It is concluded that the online availability of information on novel psychoactive drugs, such as methoxethanine, may constitute a pressing public health challenge. Better international collaboration levels and novel forms of intervention are necessary to tackle this fast-growing phenomenon.


Assuntos
Cicloexanonas/farmacologia , Cicloexilaminas/farmacologia , Drogas Ilícitas/farmacologia , Internet , Cicloexanonas/efeitos adversos , Cicloexanonas/farmacocinética , Cicloexilaminas/efeitos adversos , Cicloexilaminas/farmacocinética , Drogas Desenhadas/efeitos adversos , Drogas Desenhadas/farmacocinética , Drogas Desenhadas/farmacologia , Alucinógenos/efeitos adversos , Alucinógenos/farmacocinética , Alucinógenos/farmacologia , Humanos , Drogas Ilícitas/efeitos adversos , Drogas Ilícitas/farmacocinética , Cooperação Internacional , Ketamina/farmacocinética , Ketamina/farmacologia , Saúde Pública , Transtornos Relacionados ao Uso de Substâncias/epidemiologia , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...